The antihyperalgesic effect of venlafaxine in diabetic rats does not involve the opioid system-

Authors
F. Marchand, A. Alloui, E. Chapuy, A. Hernandez, T. Pelissier et al.


Lab
Faculté de Médecine, Laboratoire de Pharmacologie Médicale, E 9904 INSERM/UdA, Clermont-Ferrand, France.

Journal
Neuroscience Letters

Abstract
Venlafaxine (VFX) is a structurally novel antidepressant that inhibits reuptake of serotonin and norepinephrine but, unlike tricyclic antidepressants, has few side effects. The present work studies the antihyperalgesic effect of repeated administrations of VFX (five successive injections of 2.5, 5 or 10 mg/kg, s.c., every half-life) in diabetic rats with the paw pressure test and the effect of the opioid receptor antagonist naloxone (1 mg/kg, i.v.) because an opioidergic mechanism is usually considered to be involved in the analgesic effect of antidepressants. VFX induced a significant dose-dependent increase in vocalization thresholds. This effect was not reversed by naloxone. Thus, we demonstrate a clear antinociceptive effect of VFX which, unlike that of most mixed tricyclic antidepressants, does not involve the endogenous opioid system.

Source :

http://www.sciencedirect.com/science/article/pii/S0304394003002702

Publication request

Thank you for your interest in our product range and your request for this publication, which will be sent to you if the research team and the journal allow it. Our commercial team will contact you as soon as possible.